Publication Information

{'id': 'https://openalex.org/W2786715459', 'doi': 'https://doi.org/10.1158/1535-7163.targ-17-a141', 'title': 'Abstract A141: Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma', 'display_name': 'Abstract A141: Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma', 'publication_year': 2018, 'publication_date': '2018-01-01', 'ids': {'openalex': 'https://openalex.org/W2786715459', 'doi': 'https://doi.org/10.1158/1535-7163.targ-17-a141', 'mag': '2786715459'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1535-7163.targ-17-a141', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S48437117', 'display_name': 'Molecular Cancer Therapeutics', 'issn_l': '1535-7163', 'issn': ['1535-7163', '1538-8514'], 'is_oa': False, 'is_in_doaj': False, 'is_indexed_in_scopus': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5021168491', 'display_name': 'Hashim M. Aljohani', 'orcid': 'https://orcid.org/0000-0001-5333-6956'}, 'institutions': [{'id': 'https://openalex.org/I63135867', 'display_name': 'University of Cincinnati', 'ror': 'https://ror.org/01e3m7079', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I63135867']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Hashim M. Aljohani', 'raw_affiliation_strings': ['1University of Cincinnati, Cincinnati, OH;'], 'affiliations': [{'raw_affiliation_string': '1University of Cincinnati, Cincinnati, OH;', 'institution_ids': ['https://openalex.org/I63135867']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5038164784', 'display_name': 'Mohamed Aittaleb', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I63135867', 'display_name': 'University of Cincinnati', 'ror': 'https://ror.org/01e3m7079', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I63135867']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Mohamed Aittaleb', 'raw_affiliation_strings': ['1University of Cincinnati, Cincinnati, OH;'], 'affiliations': [{'raw_affiliation_string': '1University of Cincinnati, Cincinnati, OH;', 'institution_ids': ['https://openalex.org/I63135867']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5101999771', 'display_name': 'Byung Sun Park', 'orcid': 'https://orcid.org/0000-0003-1435-0784'}, 'institutions': [{'id': 'https://openalex.org/I58716616', 'display_name': 'Korea Institute of Science and Technology', 'ror': 'https://ror.org/05kzfa883', 'country_code': 'KR', 'type': 'facility', 'lineage': ['https://openalex.org/I58716616']}], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'Byung Sun Park', 'raw_affiliation_strings': ['2Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.', 'institution_ids': ['https://openalex.org/I58716616']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5080790605', 'display_name': 'So Ha Lee', 'orcid': 'https://orcid.org/0000-0002-7125-9568'}, 'institutions': [{'id': 'https://openalex.org/I58716616', 'display_name': 'Korea Institute of Science and Technology', 'ror': 'https://ror.org/05kzfa883', 'country_code': 'KR', 'type': 'facility', 'lineage': ['https://openalex.org/I58716616']}], 'countries': ['KR'], 'is_corresponding': False, 'raw_author_name': 'So Ha Lee', 'raw_affiliation_strings': ['2Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.'], 'affiliations': [{'raw_affiliation_string': '2Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.', 'institution_ids': ['https://openalex.org/I58716616']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5108290818', 'display_name': 'El Mustapha Bahassi', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I63135867', 'display_name': 'University of Cincinnati', 'ror': 'https://ror.org/01e3m7079', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I63135867']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'El Mustapha Bahassi', 'raw_affiliation_strings': ['1University of Cincinnati, Cincinnati, OH;'], 'affiliations': [{'raw_affiliation_string': '1University of Cincinnati, Cincinnati, OH;', 'institution_ids': ['https://openalex.org/I63135867']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 2, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 62}, 'biblio': {'volume': '17', 'issue': '1_Supplement', 'first_page': 'A141', 'last_page': 'A141'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11482', 'display_name': 'RNA modifications and cancer', 'score': 0.9945, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11482', 'display_name': 'RNA modifications and cancer', 'score': 0.9945, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9938, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10631', 'display_name': 'Cancer, Hypoxia, and Metabolism', 'score': 0.9899, 'subfield': {'id': 'https://openalex.org/subfields/1306', 'display_name': 'Cancer Research'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/targeted-therapy', 'display_name': 'Targeted Therapy', 'score': 0.49843645}], 'concepts': [{'id': 'https://openalex.org/C2779422266', 'wikidata': 'https://www.wikidata.org/wiki/Q5186964', 'display_name': 'Crizotinib', 'level': 4, 'score': 0.9590825}, {'id': 'https://openalex.org/C2775999482', 'wikidata': 'https://www.wikidata.org/wiki/Q18031208', 'display_name': 'ROS1', 'level': 4, 'score': 0.8049702}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.7782483}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.7199848}, {'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.6041234}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.5690415}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.5578185}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.50199986}, {'id': 'https://openalex.org/C2781230642', 'wikidata': 'https://www.wikidata.org/wiki/Q492646', 'display_name': 'Targeted therapy', 'level': 3, 'score': 0.49843645}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.49545705}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.45590988}, {'id': 'https://openalex.org/C2781018059', 'wikidata': 'https://www.wikidata.org/wiki/Q207609', 'display_name': 'Oncogene', 'level': 4, 'score': 0.45343345}, {'id': 'https://openalex.org/C101544691', 'wikidata': 'https://www.wikidata.org/wiki/Q420511', 'display_name': 'Receptor tyrosine kinase', 'level': 3, 'score': 0.4250789}, {'id': 'https://openalex.org/C29537977', 'wikidata': 'https://www.wikidata.org/wiki/Q188941', 'display_name': 'Cell cycle', 'level': 3, 'score': 0.30829132}, {'id': 'https://openalex.org/C2781182431', 'wikidata': 'https://www.wikidata.org/wiki/Q356033', 'display_name': 'Adenocarcinoma', 'level': 3, 'score': 0.26384568}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.240439}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.2349748}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.18600997}, {'id': 'https://openalex.org/C2776232967', 'wikidata': 'https://www.wikidata.org/wiki/Q6743514', 'display_name': 'Malignant pleural effusion', 'level': 3, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1535-7163.targ-17-a141', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S48437117', 'display_name': 'Molecular Cancer Therapeutics', 'issn_l': '1535-7163', 'issn': ['1535-7163', '1538-8514'], 'is_oa': False, 'is_in_doaj': False, 'is_indexed_in_scopus': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.83}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3203934256', 'https://openalex.org/W3147989365', 'https://openalex.org/W2953666243', 'https://openalex.org/W2418692205', 'https://openalex.org/W2408927976', 'https://openalex.org/W2363852307', 'https://openalex.org/W2348666640', 'https://openalex.org/W2280113021', 'https://openalex.org/W2254126652', 'https://openalex.org/W2015104488'], 'abstract_inverted_index': {'Abstract': [0], 'Glioblastoma': [1], '(GBM)': [2], 'is': [3, 83, 97, 140, 210], 'the': [4, 50, 80, 160, 227, 252, 294], 'most': [5], 'aggressive': [6], 'brain': [7], 'tumor': [8], 'in': [9, 57, 107, 169, 202, 222, 288], 'adults': [10], 'and': [11, 122, 128, 146, 193, 240, 300], 'remains': [12], 'incurable': [13], 'despite': [14], 'multimodal': [15], 'intensive': [16], 'treatment': [17], 'regimens.': [18], 'The': [19, 136], 'majority': [20], 'of': [21, 79, 132, 153, 166, 229, 256, 277, 293], 'GBM': [22, 58, 155, 206], 'tumors': [23, 35], 'show': [24], 'a': [25, 84, 98, 130, 172, 278], 'mutated': [26], 'or': [27, 43], 'overexpressed': [28], 'epidermal': [29], 'growth': [30], 'factor': [31], 'receptor': [32, 100], '(EGFR);': [33], 'however,': [34], 'treated': [36], 'with': [37, 157], 'EGFR': [38, 61, 286], 'inhibitors': [39], 'such': [40], 'as': [41, 66], 'gefitinib': [42], 'erlotinib': [44], 'inevitably': [45], 'recur.': [46], 'This': [47], 'recurrence': [48], 'highlights': [49], 'need': [51], 'to': [52, 60, 93, 149, 163, 180, 190, 212, 215, 249, 282, 285], 'identify': [53], 'signaling': [54], 'pathways': [55], 'involved': [56], 'resistance': [59, 209, 284], 'therapy': [62, 287], 'that': [63, 77], 'may': [64], 'serve': [65], 'targets': [67], 'for': [68], 'intervention.': [69], 'In': [70], 'our': [71, 230], 'recently': [72], 'published': [73], 'work,': [74], 'we': [75], 'found': [76], 'activation': [78], 'ROS1': [81, 96, 134, 150, 220, 280], 'pathway': [82], 'primary': [85], 'mechanism': [86], 'by': [87, 104, 219, 237], 'which': [88], 'glioma': [89], 'cells': [90, 156, 162, 242], 'become': [91], 'resistant': [92, 161], 'EGFR-targeted': [94], 'therapy.': [95], 'proto-oncogene': [99], 'tyrosine': [101, 185], 'kinase': [102, 186], 'activated': [103], 'chromosomal': [105], 'rearrangement': [106], 'several': [108], 'human': [109], 'cancers,': [110], 'including': [111], 'non-small': [112], 'cell': [113, 175], 'lung': [114], 'cancer': [115], '(NSCLC),': [116], 'cholangiocarcinoma,': [117], 'gastric': [118], 'cancer,': [119, 121], 'ovarian': [120], 'glioblastoma.': [123], 'We': [124], 'therefore': [125], 'designed,': [126], 'synthesized,': [127], 'screened': [129], 'series': [131], 'new': [133, 279], 'inhibitors.': [135], 'lead': [137], 'compound,': [138], 'ROS-Ic,': [139], 'very': [141], 'potent': [142], '(IC50': [143], '=': [144], '24nM)': [145], 'highly': [147], 'specific': [148], 'protein.': [151], 'Treatment': [152], 'gefitinib-resistant': [154], 'ROS1-lc': [158], 'sensitized': [159], 'low': [164], 'concentrations': [165], 'gefitinib,': [167], 'resulting': [168], 'apoptosis': [170], 'following': [171], 'prolonged': [173], 'S-phase': [174], 'cycle': [176], 'arrest.': [177], 'When': [178], 'compared': [179], 'crizotinib,': [181], 'an': [182], 'FDA-approved': [183], 'small-molecule': [184], 'inhibitor': [187, 281], 'currently': [188], 'used': [189], 'treat': [191], 'ALK-': [192], 'ROS1+': [194], 'NSCLC': [195], 'patients,': [196], 'ROS-Ic': [197], 'showed': [198], 'superior': [199], 'cytotoxic': [200], 'activity': [201], 'vitro': [203], 'towards': [204], 'ROS1-positive': [205], 'cells.': [207], 'Crizotinib': [208], 'thought': [211], 'be': [213], 'due': [214], 'abolished': [216], 'crizotinib': [217, 223], 'binding': [218, 224, 228], 'mutations': [221, 239, 245], 'pocket.': [225], 'Interestingly,': [226], 'leading': [231], 'compound': [232], 'ROS1-Ic': [233], 'was': [234], 'not': [235], 'affected': [236], 'these': [238, 244], 'crizotinib-resistant': [241], 'harboring': [243], 'were': [246], 'still': [247], 'sensitive': [248], 'ROS1-Ic,': [250], 'highlighting': [251], 'potential': [253], 'therapeutic': [254], 'value': [255], 'this': [257], 'compound.': [258], 'Citation': [259], 'Format:': [260], 'Hashim': [261], 'M.': [262], 'Aljohani,': [263], 'Mohamed': [264], 'Aittaleb,': [265], 'Byung': [266], 'Sun': [267], 'Park,': [268], 'So': [269], 'Ha': [270], 'Lee,': [271], 'El': [272], 'Mustapha': [273], 'Bahassi.': [274], 'Preclinical': [275], 'evaluation': [276], 'overcome': [283], 'glioblastoma': [289], '[abstract].': [290], 'In:': [291], 'Proceedings': [292], 'AACR-NCI-EORTC': [295], 'International': [296], 'Conference:': [297], 'Molecular': [298], 'Targets': [299], 'Cancer': [301, 312], 'Therapeutics;': [302], '2017': [303], 'Oct': [304], '26-30;': [305], 'Philadelphia,': [306], 'PA.': [307], 'Philadelphia': [308], '(PA):': [309], 'AACR;': [310], 'Mol': [311], 'Ther': [313], '2018;17(1': [314], 'Suppl):Abstract': [315], 'nr': [316], 'A141.': [317]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2786715459', 'counts_by_year': [], 'updated_date': '2025-01-19T08:50:37.578209', 'created_date': '2018-02-23'}